

Decision Letter**Uzbekistan****COVID-19 Vaccine Delivery Support****This Decision Letter sets out the Programme Terms of a Programme**

This Decision Letter forms part of the Partnership Framework Agreement (the "PFA") and together with the PFA sets out the applicable terms of the Programme (the "Programme Terms") and the Programme, including the grant and the COVID-19 CDS programme set out in this Decision Letter shall be governed by the Programme Terms. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the PFA.

The English language version of this Decision Letter shall prevail in the case of any conflict with terms expressed in any other language.

1. Country:	Uzbekistan
2. Grant number:	UZB-COVID19-CDS
3. Date of Decision Letter:	27 June 2022
4. Date of Partnership Framework Agreement:	07 February 2014
5. Programme title:	COVID-19 Vaccine Delivery Support (CDS)

6. COVID-19 CDS programme terms:

The aim of the CDS funding window is to support the country's successful roll-out and scale up of COVAX-funded doses while also strengthening health systems and immunisation programmes as specified in:

- The relevant Gavi CDS funding window guidance - please contact your Senior Country Manager for this document.
- Gavi's Transparency and Accountability Policy (TAP)¹

7. Programme duration:	2021-2022
------------------------	-----------

8. Annual Amounts: (subject to the terms of the Partnership Framework Agreement)

This is the total amount approved by Gavi for the entire duration of the programme, estimated to be disbursed under the Programme. Annual amounts are defined as per section 4.1 of the PFA. Any requested adjustments to the Annual Amounts will be subject to Gavi approval.

The Annual Amounts in this Decision Letter represent an initial CDS disbursement to support immediate needs. The country may apply for additional support under this funding window based on their needs and gaps to support the delivery of Covid-19 vaccines, as per the procedure outlined in the Gavi CDS funding window guidance. Should such support be approved at a later date, a further Decision Letter with respect to any additional approved support will be issued to reflect any updated Annual Amount.

The Country acknowledges that: (a) a proportion of or the full Annual Amount may be disbursed directly to an agreed implementing agency if agreed between Gavi and the country, such as WHO and UNICEF and expanded partners, rather than to the Country; (b) each Annual Amount may be disbursed in a number of tranches at quarterly or six-monthly

1. Transparency and accountability policy-v2.0-<https://www.gavi.org/news/document-library/transparency-and-accountability-policy> (Effective from 2014)

intervals; and (c) such disbursement shall constitute the satisfaction of the payment of that amount as if it were to have been made to the Country.

If the bank account information most recently provided to Gavi has changed or changes prior to disbursement, the country will need to complete a bank account information form. Please contact gavihss@gavi.org for the form.

Programme Year	2021	2022	Total
CDS - Early Access	2,404,057.00	0.00	2,404,057.00
CDS - Need based Funding	0.00	4,156,334.60	4,156,334.60
Total	2,404,057.00	4,156,334.60	6,560,391.60

9. Outstanding comments / clarifications: None

10. Documents to be delivered: None

11. Reporting and Assurance requirements:

In accordance with Gavi's Transparency and Accountability Policy (TAP), participants must ensure that all support received from the COVAX Facility is managed in a transparent and accountable manner through systems that include appropriate oversight mechanisms and that the support is used according with the purposes for which it is provided.

All CDS recipients will be required to provide both programmatic and financial reporting to Gavi on a 6-monthly basis. Countries are required to provide outcome reporting through the WHO-UNICEF COVID-19 monthly module (via the electronic Joint Reporting Form). Recipients will also be strongly encouraged to participate in broader COVID-19 evaluation and learning related efforts.

The Country will be expected to include the activities funded by this initial CDS programme disbursement along with the respective budget while applying for any additional CDS programme support. In case the country does not intend to request additional funding through this window, an expenditure report detailing how this initial CDS disbursement was spent will be required within 3 months of completion, with any unspent balances returned upon completion of audit and no later than 6 months from completion.

Gavi may deploy a Monitoring Agent to provide independent assurance over delivery of programmatic and financial outcomes, including use of funds as set forth in the program budget for the roll-out and scale-up of COVID-19 vaccines supplied through the Covax Facility. The Government shall use its best efforts to ensure the Monitoring Agent has access to people, processes, and documents, as needed for the smooth conduct of their work.

Gavi may conduct an investigation and/or audit at any time in the the participating territory through its own authorised representatives or agents to assess the proper use of Gavi provided vaccines or funds. The Country shall cooperate fully in relation to any Gavi investigation and/or audit by providing a safe working environment; ensuring the personal safety of those conducting the investigation or audit; and, facilitating full and unhindered access at all times to all programme documentation, Government personnel and any premises where Programme Documents are held or Programme activities have been undertaken.

The Government shall use its best endeavours to pursue any individuals or entities involved in illegal or unlawful activities in accordance with the laws of the Country and inform Gavi on the outcome of any cases.

If there is any material Misuse, Gavi reserves the right to be reimbursed by the Government for up to 100% of the reasonable investigation costs to be determined on a case-by-case basis.

12. Other conditions - the following terms and conditions shall apply to the Programme: None



Sam Muller, Acting Director, Immunisation Financing & Sustainability